Home LiteratureArticle Details
PMID: 28052991 Published · ppublish English Journal Article Review

Myeloid-Derived Suppressor Cells.

Cancer immunology research ·Vol. 5 ·No. 1 ·2017-00-00 ·Pages 3-8

Gabrilovich DI

Abstract

Myeloid cells developed evolutionarily as a major mechanism to protect the host. They evolved as a critical barrier against infections and are important contributors to tissue remodeling. However, in cancer, myeloid cells are largely converted to serve a new master-tumor cells. This process is epitomized by myeloid-derived suppressor cells (MDSC). These cells are closely related to neutrophils and monocytes. MDSCs are not present in the steady state of healthy individuals and appear in cancer and in pathologic conditions associated with chronic inflammation or stress. These cells have emerged as an important contributor to tumor progression. Ample evidence supports a key role for MDSCs in immune suppression in cancer, as well as their prominent role in tumor angiogenesis, drug resistance, and promotion of tumor metastases. MDSCs have a fascinating biology and are implicated in limiting the effects of cancer immunotherapy. Therefore, targeting these cells may represent an attractive therapeutic opportunity. Cancer Immunol Res; 5(1); 3-8. ©2016 AACR.

MeSH Terms
Animals Biomarkers Cell Differentiation Humans Immunomodulation Molecular Targeted Therapy Myeloid-Derived Suppressor Cells/cytology,drug effects,immunology,metabolism Neoplasms/genetics,immunology,metabolism,pathology Organ Specificity/immunology Phenotype Signal Transduction
Chemicals
Biomarkers
Authors & Affiliations
1 authors, click to expand affiliations / ORCID
Gabrilovich Dmitry I
The Wistar Institute, Philadelphia, Pennsylvania. [email protected].
References (77)
77 references, click to expand
  1. Peptide-based systems analysis of inflammation induced myeloid-derived suppressor cells reveals diverse signaling pathways.
    Proteomics. 2016 Jul;16(13):1881-8 PMID: 27193397
  2. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer.
    Nat Med. 2007 Jul;13(7):828-35 PMID: 17603493
  3. The terminology issue for myeloid-derived suppressor cells.
    Cancer Res. 2007 Jan 1;67(1):425; author reply 426 PMID: 17210725
  4. Subpopulations of myeloid-derived suppressor cells impair T cell responses through independent nitric oxide-related pathways.
    Int J Cancer. 2014 Jun 15;134(12):2853-64 PMID: 24259296
  5. All-trans-retinoic acid improves differentiation of myeloid cells and immune response in cancer patients.
    Cancer Res. 2006 Sep 15;66(18):9299-307 PMID: 16982775
  6. Invasive breast cancer reprograms early myeloid differentiation in the bone marrow to generate immunosuppressive neutrophils.
    Proc Natl Acad Sci U S A. 2015 Feb 10;112(6):E566-75 PMID: 25624500
  7. Population alterations of L-arginase- and inducible nitric oxide synthase-expressed CD11b+/CD14⁻/CD15+/CD33+ myeloid-derived suppressor cells and CD8+ T lymphocytes in patients with advanced-stage non-small cell lung cancer.
    J Cancer Res Clin Oncol. 2010 Jan;136(1):35-45 PMID: 19572148
  8. Lectin-type oxidized LDL receptor-1 distinguishes population of human polymorphonuclear myeloid-derived suppressor cells in cancer patients.
    Sci Immunol. 2016 Aug;1(2): PMID: 28417112
  9. Transcriptional regulation of myeloid-derived suppressor cells.
    J Leukoc Biol. 2015 Dec;98 (6):913-22 PMID: 26337512
  10. Regulation of dendritic cell differentiation and antitumor immune response in cancer by pharmacologic-selective inhibition of the janus-activated kinase 2/signal transducers and activators of transcription 3 pathway.
    Cancer Res. 2005 Oct 15;65(20):9525-35 PMID: 16230418
  11. Arginase I in myeloid suppressor cells is induced by COX-2 in lung carcinoma.
    J Exp Med. 2005 Oct 3;202(7):931-9 PMID: 16186186
  12. Phase I/II Study of Metastatic Melanoma Patients Treated with Nivolumab Who Had Progressed after Ipilimumab.
    Cancer Immunol Res. 2016 Apr;4(4):345-53 PMID: 26873574
  13. ER stress regulates myeloid-derived suppressor cell fate through TRAIL-R-mediated apoptosis.
    J Clin Invest. 2014 Jun;124(6):2626-39 PMID: 24789911
  14. Tadalafil reduces myeloid-derived suppressor cells and regulatory T cells and promotes tumor immunity in patients with head and neck squamous cell carcinoma.
    Clin Cancer Res. 2015 Jan 1;21(1):39-48 PMID: 25320361
  15. Tadalafil augments tumor specific immunity in patients with head and neck squamous cell carcinoma.
    Clin Cancer Res. 2015 Jan 1;21(1):30-8 PMID: 25564570
  16. Unopposed production of granulocyte-macrophage colony-stimulating factor by tumors inhibits CD8+ T cell responses by dysregulating antigen-presenting cell maturation.
    J Immunol. 1999 May 15;162(10):5728-37 PMID: 10229805
  17. Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab.
    PLoS One. 2014 Feb 03;9(2):e87705 PMID: 24498358
  18. Myeloid-derived suppressor cell heterogeneity in human cancers.
    Ann N Y Acad Sci. 2014 Jun;1319:47-65 PMID: 24965257
  19. Anti-inflammatory triterpenoid blocks immune suppressive function of MDSCs and improves immune response in cancer.
    Clin Cancer Res. 2010 Mar 15;16(6):1812-23 PMID: 20215551
  20. S1PR1-STAT3 signaling is crucial for myeloid cell colonization at future metastatic sites.
    Cancer Cell. 2012 May 15;21(5):642-54 PMID: 22624714
  21. Tumor-infiltrating myeloid cells induce tumor cell resistance to cytotoxic T cells in mice.
    J Clin Invest. 2011 Oct;121(10):4015-29 PMID: 21911941
  22. GVHD-associated, inflammasome-mediated loss of function in adoptively transferred myeloid-derived suppressor cells.
    Blood. 2015 Sep 24;126(13):1621-8 PMID: 26265697
  23. Toward harmonized phenotyping of human myeloid-derived suppressor cells by flow cytometry: results from an interim study.
    Cancer Immunol Immunother. 2016 Feb;65(2):161-9 PMID: 26728481
  24. History of myeloid-derived suppressor cells.
    Nat Rev Cancer. 2013 Oct;13(10 ):739-52 PMID: 24060865
  25. Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.
    Sci Transl Med. 2014 May 21;6(237):237ra67 PMID: 24848257
  26. CD14(+)S100A9(+) monocytic myeloid-derived suppressor cells and their clinical relevance in non-small cell lung cancer.
    Am J Respir Crit Care Med. 2012 Nov 15;186(10):1025-36 PMID: 22955317
  27. Expression of Cationic Amino Acid Transporter 2 Is Required for Myeloid-Derived Suppressor Cell-Mediated Control of T Cell Immunity.
    J Immunol. 2015 Dec 1;195(11):5237-50 PMID: 26491198
  28. Distinct Functions of Senescence-Associated Immune Responses in Liver Tumor Surveillance and Tumor Progression.
    Cancer Cell. 2016 Oct 10;30(4):533-547 PMID: 27728804
  29. A circulating subpopulation of monocytic myeloid-derived suppressor cells as an independent prognostic/predictive factor in untreated non-small lung cancer patients.
    J Immunol Res. 2014;2014:659294 PMID: 25436215
  30. Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards.
    Nat Commun. 2016 Jul 06;7:12150 PMID: 27381735
  31. The Role of Myeloid-Derived Suppressor Cells in Patients with Solid Tumors: A Meta-Analysis.
    PLoS One. 2016 Oct 25;11(10 ):e0164514 PMID: 27780254
  32. Coordinated regulation of myeloid cells by tumours.
    Nat Rev Immunol. 2012 Mar 22;12(4):253-68 PMID: 22437938
  33. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment.
    J Exp Med. 2010 Oct 25;207(11):2439-53 PMID: 20876310
  34. Transcriptomic analysis comparing tumor-associated neutrophils with granulocytic myeloid-derived suppressor cells and normal neutrophils.
    PLoS One. 2012;7(2):e31524 PMID: 22348096
  35. Hypoxia-induced lysyl oxidase is a critical mediator of bone marrow cell recruitment to form the premetastatic niche.
    Cancer Cell. 2009 Jan 6;15(1):35-44 PMID: 19111879
  36. Tumor-induced myeloid dysfunction and its implications for cancer immunotherapy.
    Cancer Immunol Immunother. 2015 Jan;64(1):1-13 PMID: 25432147
  37. Tumor-associated neutrophils stimulate T cell responses in early-stage human lung cancer.
    J Clin Invest. 2014 Dec;124(12):5466-80 PMID: 25384214
  38. Polarization of tumor-associated neutrophil phenotype by TGF-beta: "N1" versus "N2" TAN.
    Cancer Cell. 2009 Sep 8;16(3):183-94 PMID: 19732719
  39. Generation of a new therapeutic peptide that depletes myeloid-derived suppressor cells in tumor-bearing mice.
    Nat Med. 2014 Jun;20(6):676-81 PMID: 24859530
  40. Epigenetic silencing of retinoblastoma gene regulates pathologic differentiation of myeloid cells in cancer.
    Nat Immunol. 2013 Mar;14(3):211-20 PMID: 23354483
  41. Drafting the proteome landscape of myeloid-derived suppressor cells.
    Proteomics. 2016 Jan;16(2):367-78 PMID: 26403437
  42. Elevated endoplasmic reticulum stress reinforced immunosuppression in the tumor microenvironment via myeloid-derived suppressor cells.
    Oncotarget. 2014 Dec 15;5(23):12331-45 PMID: 25514597
  43. Tumour-infiltrating Gr-1+ myeloid cells antagonize senescence in cancer.
    Nature. 2014 Nov 6;515(7525):134-7 PMID: 25156255
  44. Antibody-Mediated Phosphatidylserine Blockade Enhances the Antitumor Responses to CTLA-4 and PD-1 Antibodies in Melanoma.
    Cancer Immunol Res. 2016 Jun;4(6):531-40 PMID: 27045021
  45. Chemokine nitration prevents intratumoral infiltration of antigen-specific T cells.
    J Exp Med. 2011 Sep 26;208(10):1949-62 PMID: 21930770
  46. Myeloid-derived suppressor cells in the development of lung cancer.
    Cancer Immunol Res. 2014 Jan;2(1):50-8 PMID: 24778162
  47. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models.
    Proc Natl Acad Sci U S A. 2009 Apr 21;106(16):6742-7 PMID: 19346489
  48. Tumor-induced tolerance and immune suppression depend on the C/EBPbeta transcription factor.
    Immunity. 2010 Jun 25;32(6):790-802 PMID: 20605485
  49. Mesenchymal transition and dissemination of cancer cells is driven by myeloid-derived suppressor cells infiltrating the primary tumor.
    PLoS Biol. 2011 Sep;9(9):e1001162 PMID: 21980263
  50. CD45 Phosphatase Inhibits STAT3 Transcription Factor Activity in Myeloid Cells and Promotes Tumor-Associated Macrophage Differentiation.
    Immunity. 2016 Feb 16;44(2):303-15 PMID: 26885857
  51. Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.
    Proc Natl Acad Sci U S A. 2014 Aug 12;111(32):11774-9 PMID: 25071169
  52. Impaired gp100-Specific CD8(+) T-Cell Responses in the Presence of Myeloid-Derived Suppressor Cells in a Spontaneous Mouse Melanoma Model.
    J Invest Dermatol. 2015 Nov;135(11):2785-93 PMID: 26121214
  53. Targeting the interleukin-6/Jak/stat pathway in human malignancies.
    J Clin Oncol. 2012 Mar 20;30(9):1005-14 PMID: 22355058
  54. Tumour-mediated upregulation of chemoattractants and recruitment of myeloid cells predetermines lung metastasis.
    Nat Cell Biol. 2006 Dec;8(12):1369-75 PMID: 17128264
  55. Autocrine-paracrine VEGF loops potentiate the maturation of megakaryocytic precursors through Flt1 receptor.
    Blood. 2003 Feb 15;101(4):1316-23 PMID: 12406876
  56. Immature myeloid cells directly contribute to skin tumor development by recruiting IL-17-producing CD4+ T cells.
    J Exp Med. 2015 Mar 9;212(3):351-67 PMID: 25667306
  57. Comprehensive review on the HSC70 functions, interactions with related molecules and involvement in clinical diseases and therapeutic potential.
    Pharmacol Ther. 2012 Dec;136(3):354-74 PMID: 22960394
  58. Gemcitabine directly inhibits myeloid derived suppressor cells in BALB/c mice bearing 4T1 mammary carcinoma and augments expansion of T cells from tumor-bearing mice.
    Int Immunopharmacol. 2009 Jul;9(7-8):900-9 PMID: 19336265
  59. Myeloid-derived suppressor cells enhance stemness of cancer cells by inducing microRNA101 and suppressing the corepressor CtBP2.
    Immunity. 2013 Sep 19;39(3):611-21 PMID: 24012420
  60. Can the suppressive activity of myeloid-derived suppressor cells be "chop"ped?
    Immunity. 2014 Sep 18;41(3):341-2 PMID: 25238087
  61. Gemcitabine selectively eliminates splenic Gr-1+/CD11b+ myeloid suppressor cells in tumor-bearing animals and enhances antitumor immune activity.
    Clin Cancer Res. 2005 Sep 15;11(18):6713-21 PMID: 16166452
  62. Bone marrow PMN-MDSCs and neutrophils are functionally similar in protection of multiple myeloma from chemotherapy.
    Cancer Lett. 2016 Feb 1;371(1):117-24 PMID: 26639197
  63. The Nature of Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.
    Trends Immunol. 2016 Mar;37(3):208-20 PMID: 26858199
  64. Targeting immune suppression with PDE5 inhibition in end-stage multiple myeloma.
    Cancer Immunol Res. 2014 Aug;2(8):725-31 PMID: 24878583
  65. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab.
    Cancer Immunol Immunother. 2014 Mar;63(3):247-57 PMID: 24357148
  66. MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy.
    Int Immunopharmacol. 2011 Jul;11(7):856-61 PMID: 21315783
  67. RORC1 Regulates Tumor-Promoting "Emergency" Granulo-Monocytopoiesis.
    Cancer Cell. 2015 Aug 10;28(2):253-69 PMID: 26267538
  68. The stress-response sensor chop regulates the function and accumulation of myeloid-derived suppressor cells in tumors.
    Immunity. 2014 Sep 18;41(3):389-401 PMID: 25238096
  69. Neutrophils and granulocytic myeloid-derived suppressor cells: immunophenotyping, cell biology and clinical relevance in human oncology.
    Cancer Immunol Immunother. 2012 Aug;61(8):1155-67 PMID: 22692756
  70. 5-Fluorouracil selectively kills tumor-associated myeloid-derived suppressor cells resulting in enhanced T cell-dependent antitumor immunity.
    Cancer Res. 2010 Apr 15;70(8):3052-61 PMID: 20388795
  71. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy.
    Cancer Metastasis Rev. 2011 Mar;30(1):83-95 PMID: 21249423
  72. Proteomic pathway analysis reveals inflammation increases myeloid-derived suppressor cell resistance to apoptosis.
    Mol Cell Proteomics. 2011 Mar;10(3):M110.002980 PMID: 21191032
  73. Nitroaspirin corrects immune dysfunction in tumor-bearing hosts and promotes tumor eradication by cancer vaccination.
    Proc Natl Acad Sci U S A. 2005 Mar 15;102(11):4185-90 PMID: 15753302
  74. A core of kinase-regulated interactomes defines the neoplastic MDSC lineage.
    Oncotarget. 2015 Sep 29;6(29):27160-75 PMID: 26320174
  75. Therapeutic regulation of myeloid-derived suppressor cells and immune response to cancer vaccine in patients with extensive stage small cell lung cancer.
    Cancer Immunol Immunother. 2013 May;62(5):909-18 PMID: 23589106
  76. Gr-1+CD11b+ myeloid cells tip the balance of immune protection to tumor promotion in the premetastatic lung.
    Cancer Res. 2010 Aug 1;70(15):6139-49 PMID: 20631080
  77. Vascular endothelial growth factor inhibits the development of dendritic cells and dramatically affects the differentiation of multiple hematopoietic lineages in vivo.
    Blood. 1998 Dec 1;92(11):4150-66 PMID: 9834220
Article Info
Journal
Cancer immunology research
Abbr.
Cancer Immunol Res
ISSN
2326-6074
DOI
10.1158/2326-6066.CIR-16-0297
Email
[email protected]
Published
2017-00-00
Pages
3-8
Language
English
Region
United States
NLM ID
101614637
PMCID
PMC5426480
Subset
IM
Grants
NCI NIH HHS · R01 CA165065 · United States
NCI NIH HHS · P30 CA010815 · United States
NCI NIH HHS · R01 CA141438 · United States
NCI NIH HHS · R01 CA177646 · United States
NCI NIH HHS · R01 CA084488 · United States
NCI NIH HHS · R01 CA100062 · United States
External Links
PubMed source DOI: 10.1158/2326-6066.CIR-16-0297 PMC Full Text View journal details
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2